
Kalon
1.2K posts

Kalon
@Kalonshaka
Years of R&D experience (not an advisor of any kind, just my opinions based on heavy research)




David Sinclair just revealed one of the biggest studies on nattokinase. A comprehensive Chinese study of 1,067 people found that nattokinase reversed cardiovascular disease by removing up to 95% of arterial plaque in one year. This supplement is an enzyme from fermented soybeans and costs almost nothing. Sinclair has been taking it daily for a couple of years. He measures his carotid artery with ultrasound and says there's no plaque buildup at all. Peter Diamandis takes it too. He believes you need at least 6,000 fibrinolytic units per day to reap the benefits. For context: • Statins cost hundreds per month and come with side effects. • Surgical interventions can cost thousands of dollars Nattokinase costs a fraction of both. Sinclair's caveat: "Do this with the knowledge of your physician." But the data exists. A study of over 1,000 people and up to 95% plaque removal in just 12 months. And the man whose lab is reversing aging takes it every day. — David Sinclair (@davidasinclair) on Peter Diamandis' (@PeterDiamandis) Moonshots podcast PS. David Sinclair is speaking at SynBioBeta on May 6th this year, discussing the science of slowing and reversing aging. If longevity is the world you're in, the investors, partners, and scientists shaping this space will be in the room. Grab your ticket in the comments below.







🚨🚨 We previously exposed the PubPeer “PubSmear” Network Mob's signature tactic: 'Working in coordination with fellow network members, they employ the mob’s signature tactic of the ‘PARTIAL TRUTH’ —selectively highlighting fragments of information to construct PUBPEER (aka ‘PUBSMEAR’) dossiers against the scientists they target. Along the way, many additional researchers become collateral damage, serving to conceal the network’s primary targets.' ⚠️ And their central distortion: 'Their central tactic is to falsely equate the number of PubPeer entries with the number of fraudulent papers upon which their harassment, smearing, and defamation campaigns stand — a deliberate distortion designed to mislead the academic community, media, and institutions.' 📌Now Nobel Laureate Thomas C. Südhof confirms the real damage in his Lindau 2025 lecture: 'The cost to especially junior scientists has been enormous... Does it matter if a tree falls in the forest and no one is around to hear it?' Every scientist, researcher, and postgraduate student needs to know about this scandal. What we’ve exposed is only the tip of the iceberg. Watch our 9-min bombshell + @NobelPrize Laureate @Stanford Professor Thomas C. Südhof's Lindau 2025 lecture segment below 👇 Watch it. Spread it. Far more is coming. Stay tuned. @SciGuardians 🔱

🚨 Holden Thorp Puzzle — Full Q&A Release: The Perpetrator They Tried to Shield Today, we are releasing — in full — the complete set of questions sent by compromised journalist Holly Else and the official ScienceGuardians™ responses exactly as provided to her on 2 May 2025. These Q&As form just one segment of a broader exchange spanning April to June 2025, which we previously published in full (link in the first comment). But this release is different. It places the entire Q&A itself — the heart of her attempted narrative control — into the public record. This document is not merely correspondence. It is evidence — a record of how Else, who had earlier played a central role in defaming @NobelPrize laureate and distinguished @Stanford Professor Thomas C. Südhof through her 1 May 2024 @ScienceMagazine article, under Holden Thorp’s leadership, now returned ready to serve the same mob network once more. Except this time, she acted under the umbrella of another compromised outlet serving the PubPeer “PubSmear” Network Mob’s interests: the news section of @Nature. Her objective was unmistakable: shield Elisabeth Bik from exposure — a mission that failed spectacularly. Because the 🚨 BOMBSHELL SCIENCE INTEGRITY SCANDAL we released on 17 NOV 2025 showed the world exactly what Else was trying to prevent: that Bik and the PubPeer “PubSmear” Network Mob had built an operation dependent on deception, censorship, and narrative manipulation. And that is why they panicked when a 100-follower account began exposing them in early April 2025. They understood that once their tactics, alliances, and concealed misconduct were illuminated, their entire machinery of manufactured authority and anonymous harassment would begin to collapse. And collapse it has. 📌 This email exchange and the full Q&A release are now part of the public record. They reveal: • Else’s reliance on deceptive communication channels • Her attempt to shape the article’s narrative before hearing our side • Her prioritization of PubPeer “PubSmear” Network Mob talking points • Her tactical withdrawal once it became clear that proceeding with the article would further compromise and expose them • Her alignment with the same network later exposed for 100% censorship of critiques against their own flawed work 👉 The link to the full Q&A — unedited, unaltered, and preserved exactly as delivered on 2 May 2025 — will appear in the first comment. This is only one piece of the Holden Thorp Puzzle. More is coming. 🔱 Follow @SciGuardians for the next release.

🚨NEW: Tucker Carlson *BLOWN AWAY* as Wikipedia Co-Founder Larry Sanger walks him through site’s "BLACKLIST"🤯🤣 "Oh, wow ... this is kind of incredible!" "This is so funny! This is amazing!" @DailyCaller


What must be done? Integrity won’t be saved by those who corrupted it. It must be reclaimed by those willing to name what others fear—and build what others failed to imagine. ScienceGuardians™ offers a post-publication peer review platform rooted in ethics, identity verification, and transparency. • One account per user—no multiple identities or sockpuppets. • Each contributor is identity‑verified—not by us, but by virtue of their real institutional affiliation and academic credentials. • Users may remain publicly anonymous, but their identity is always confirmed internally—eliminating pseudonymous drive‑by attacks. • Once verified, users are not subject to moderation—all contributions publish immediately. • Structured, publication‑specific threads keep discussions focused and constructive. • Underpinning all of this is a set of community-anchored ethics guidelines to support authors, editors, reviewers, and institutions in upholding the highest professional standards: 🔗 scienceguardians.com/resources/main We propose: ✅ Verified accountability for all post-publication commentary ✅ Transparent retraction protocols ✅ Institutional oversight of online integrity platforms – to distinguish critique from coordinated abuse. ❌ No more anonymous mass accusations. ✅ Independent reform by scientists—not mobs. “We are not against critique. We are against corruption in the name of critique.” The real question is not how many retractions we’ve enforced. It’s how many truths we’ve silenced along the way. 📌 Read the full article: theanalyticalscientist.com/issues/2025/ar…





Th Epstein Files have reached the McCarthy-era stage where innocent people are being slandered. We need to distinguish between evildoers and those who ‘appear’ in the Epstein files, but have done nothing wrong. I am hearing of totally innocent people being forced to resign from boards etc. because their name appears somewhere in the documents. Let’s return to a world where people are presumed innocent until they are proven guilty.

$SAVA @RobertKennedyJr @SecKennedy @joerogan @MikeBenzCyber Long awaited, the additional data analysis from the Cassava Science simufilam Phase 3 (Rethink and Refocus trials) in mild-moderate Alzheimer‘s has been published in Journal of Prevention of Alzheimer’s Diseas: #sec0023" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl…
As anticipated there were major design flaws, impacting both of these large studies (~1800 patients in total), including: 1). problems with the use of ptau181 for screening, likely allowing portions of MCI or very early AD patients which is not the intended patient population for these trials, given the unprecedented slow placebo group decline for a presumably classified mild-moderate patient population in both studies, and 2). Questionable use of ADAS-COG12 instead of the more discriminating ADAS-COG13 in light of the likely highly variable “mild” population in both studies. For example, in the MABs (Lecanemab and donanemab) approved studies in MCI-Mild Alzheimers patients the more discriminatory ADAS-COG13 was used. 3). early stoppage of Refocus study (an 18 month trial) that made the final 18 month time-point reliant on data modeling due to nearly 50% missing data and the result of data modeling that shows ADAS-COG12 placebo flattening from 12-18 months, see graph below…which is absurd given historical rates of significant dramatic decline from 12-18 months in Alzheimer’s patients classified as mild-moderate. Despite these major trial flaws, incredibly, in the pre-specified mild group analysis for the 18 month Refocus study (714 patients-a very large group), there was a dramatically LARGE statistically significant (p <0.05) ADAS-COG12 effect from simufilam treatment in the preceding time-points (1 month, 6 months, 9 months, 12 months, and 15 months, see graph below), prior to 18 month time-point (end of study and the time-point with the significant missing data). This result is for an astonishing 714 patients In the combined 3-arms (100 mg, 50 mg, and placebo groups). In addition the change from baseline on ADAS-Cog12 in the highest half (≥ 67 pg/mL) of plasma p-tau181 from the ITT population of RETHINK (367 patients) showed large differences at Weeks 28, 40 and 52 (p=0.009, p=0.048 and p=0.036), graph below. This is for an astonishing 367 patients! Given that both trials failed their primary and secondary endpoints, the authors of this publication are forced to formally call these additional data analyses “nominal“ results (the Refocus pre-specified, 714 mild patients and Rethink post-hoc analyses for highest half (≥ 67 pg/mL) of plasma p-tau181, 367 patients). but I beg to differ, and also in light of the flawed elements of the study described above. I compel @MartyMakary @US_FDA to take note of these ”nominal results” as well as the entire scientific community @DrJBhattacharya @RWMaloneMD @SabinehazanMD @DrJeffCummings and think pragmatically what this science and simufilam could mean to the Alzheimer’s community. @alzassociation @CTADconference Also recall that the pubsmear mob and their short and distort sponsors tried to discredit Cassava Sciences, by attacking simufilam and the FLNA science, Dr. Hoau-Yan Wang, amongst many other targets as also discussed by @SciGuardians and recently attacks against @weldeiry. The pubsmear and short and distort anti-competitive forces led to a bogus FDA citizens petition against Cassava Sciences, an SEC $40 million fine of Cassava Sciences, fake media (NYT, WSJ, Science Magazine, others) blitz against Cassava, class-action lawsuits as a result typical of such short and distort campaigns perpetrated by Wallstreet, CUNY investigation of Dr. Wang, and Biden’s DOJ attempted prosecution, which fell apart after CUNY provided exculpatory evidence and DOJ unprecedentedly dropping all prosecution at the 11th hour this past October, knowing their case was bogus! This all showcases complete injustice, criminal short and distort, and anti-competitive forces against real and valid science that was perpetrated against Cassava and Dr. Wang, and this is all documented in time.

$SAVA @RobertKennedyJr @SecKennedy @joerogan @MikeBenzCyber Long awaited, the additional data analysis from the Cassava Science simufilam Phase 3 (Rethink and Refocus trials) in mild-moderate Alzheimer‘s has been published in Journal of Prevention of Alzheimer’s Diseas: #sec0023" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl…
As anticipated there were major design flaws, impacting both of these large studies (~1800 patients in total), including: 1). problems with the use of ptau181 for screening, likely allowing portions of MCI or very early AD patients which is not the intended patient population for these trials, given the unprecedented slow placebo group decline for a presumably classified mild-moderate patient population in both studies, and 2). Questionable use of ADAS-COG12 instead of the more discriminating ADAS-COG13 in light of the likely highly variable “mild” population in both studies. For example, in the MABs (Lecanemab and donanemab) approved studies in MCI-Mild Alzheimers patients the more discriminatory ADAS-COG13 was used. 3). early stoppage of Refocus study (an 18 month trial) that made the final 18 month time-point reliant on data modeling due to nearly 50% missing data and the result of data modeling that shows ADAS-COG12 placebo flattening from 12-18 months, see graph below…which is absurd given historical rates of significant dramatic decline from 12-18 months in Alzheimer’s patients classified as mild-moderate. Despite these major trial flaws, incredibly, in the pre-specified mild group analysis for the 18 month Refocus study (714 patients-a very large group), there was a dramatically LARGE statistically significant (p <0.05) ADAS-COG12 effect from simufilam treatment in the preceding time-points (1 month, 6 months, 9 months, 12 months, and 15 months, see graph below), prior to 18 month time-point (end of study and the time-point with the significant missing data). This result is for an astonishing 714 patients In the combined 3-arms (100 mg, 50 mg, and placebo groups). In addition the change from baseline on ADAS-Cog12 in the highest half (≥ 67 pg/mL) of plasma p-tau181 from the ITT population of RETHINK (367 patients) showed large differences at Weeks 28, 40 and 52 (p=0.009, p=0.048 and p=0.036), graph below. This is for an astonishing 367 patients! Given that both trials failed their primary and secondary endpoints, the authors of this publication are forced to formally call these additional data analyses “nominal“ results (the Refocus pre-specified, 714 mild patients and Rethink post-hoc analyses for highest half (≥ 67 pg/mL) of plasma p-tau181, 367 patients). but I beg to differ, and also in light of the flawed elements of the study described above. I compel @MartyMakary @US_FDA to take note of these ”nominal results” as well as the entire scientific community @DrJBhattacharya @RWMaloneMD @SabinehazanMD @DrJeffCummings and think pragmatically what this science and simufilam could mean to the Alzheimer’s community. @alzassociation @CTADconference Also recall that the pubsmear mob and their short and distort sponsors tried to discredit Cassava Sciences, by attacking simufilam and the FLNA science, Dr. Hoau-Yan Wang, amongst many other targets as also discussed by @SciGuardians and recently attacks against @weldeiry. The pubsmear and short and distort anti-competitive forces led to a bogus FDA citizens petition against Cassava Sciences, an SEC $40 million fine of Cassava Sciences, fake media (NYT, WSJ, Science Magazine, others) blitz against Cassava, class-action lawsuits as a result typical of such short and distort campaigns perpetrated by Wallstreet, CUNY investigation of Dr. Wang, and Biden’s DOJ attempted prosecution, which fell apart after CUNY provided exculpatory evidence and DOJ unprecedentedly dropping all prosecution at the 11th hour this past October, knowing their case was bogus! This all showcases complete injustice, criminal short and distort, and anti-competitive forces against real and valid science that was perpetrated against Cassava and Dr. Wang, and this is all documented in time.
There's a social network map floating around X that someone created that lists roughly 100 people including 13 people as a close friend, including Laura and me. Epstein is also listed as a close friend of the creator. An anonymous X account is implying that means Epstein and I were close friends. To set the record perfectly straight: neither Laura nor I ever met or spoke with Epstein. Ever. The X account that makes this claim has repeatedly slandered me over the past year. I'm sure he will continue to do so. He won't stop our work.



🚨 Evidence drops — follow the money and the playbook these predator billionaires use to hijack science: 👉 See the full thread exposing the Bill Gates-Jeffrey Epstein-ResearchGate scandal: How Gates & Epstein secretly bought CONTROL over what scientists discover, share, and believe—through ResearchGate's platform dominance, insider hype, and leverage on publishers. Leaked emails, contracts, and patterns laid bare. x.com/SciGuardians/s… 👉 See the accumulated evidence exposing the John & Laura Arnold "Research Integrity Machine" scandal: Millions poured over a decade into PubPeer (aka "PubSmear"), Retraction Watch/Center for Scientific Integrity, Center for Open Science, Sense About Science & more—to force targeted retractions, orchestrate smears/defamation via the PubPeer "PubSmear" Network Mob, instill fear, hide agendas, and DICTATE what science can say. x.com/SciGuardians/s… @SecKennedy @DrJBhattacharya @elonmusk @BillAckman @HHS_ORI @NIH @C0PE

⚡️#BREAKING Insane document found in Epstein files ID: EFTA02416819


Orchestrated malicious attacks by PubPeer mob were noticed by colleagues like @Kevin_McKernan & also exposed by @SciGuardians but have not stopped. Attacks continue with public online harassment around the clock unchecked by government or anyone else with damaging consequences.

